Sparsentan: First Approval
Yahiya Y. Syed
Abstract
Sparsentan (FILSPARI™) is an oral, dual endothelin angiotensin receptor antagonist that is being developed by Travere Therapeutics for the treatment of immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis (FSGS). In February 2023, sparsentan received accelerated approval in the USA for reducing proteinuria in adults with primary IgA nephropathy who are at risk of rapid disease progression. This article summarizes the milestones in the development of sparsentan leading to this first approval for IgA nephropathy.
Topics & Concepts
MedicineNephropathyProteinuriaFocal segmental glomerulosclerosisInternal medicineEndocrinologyKidneyDiabetes mellitusRenal Diseases and GlomerulopathiesMast cells and histamineCoagulation, Bradykinin, Polyphosphates, and Angioedema